A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-ribavirin

Memorias do Instituto Oswaldo Cruz

Volumn 107, Issue 7, 2012, Pages 888-892

  Ramos, Juliene Antonio ^a,b,c   Ramos, Ana Lúcia de Araújo ^a   Hoffmann, Luisa ^a,c   Perez, Renata de Mello ^a   Coelho, Henrique Sérgio Moraes ^a   Ürményi, Turán Péter ^a,c   Silva, Rosane ^a,c   Rondinelli, Edson ^a,c   Villela Nogueira, Cristiane Alves ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO FEDERAL DE EDUCAÇÃO   (Brazil)

^c Ministério de Ciência Tecnologia e Inovação Salvador   (Brazil)

Author keywords

Hepatitis C; IL28B; Rs12979860; Rs8099917; Treatment

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN; VIRUS RNA;

ARTICLE; BRAZIL; COHORT ANALYSIS; DRUG COMBINATION; FEMALE; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; BRAZIL; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1;

EID: 84869187570     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762012000700008     Document Type: Article

References (32)

1. Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, Mitsui F, Hiraga N, Imamura M, Takahashi S, Ohishi W, Arihiro K, Kubo M, Nakamura Y, Chayama K 2010. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 53: 439-443.
2. Balagopal A, Thomas DL, Thio CL 2010. IL28B and the control of hepatitis C virus infection. Gastroenterology 139: 1865-1876.
3. Bochud PY, Bibert S, Kutalik Z, Patin E, Guergnon I, Nalpas B, Goossens N, Kuske L, Müllhaupt B, Gergach T, Heim MH, Moradpour D, Gerny A, Malinverni R, Regenass S, Dollenmaier G, Hersch H, Martinetti G, Gorgiewski M, Bourlièrre M, Poynard T, Theodorou J, Abel L, Pol S, Dufour JF, Negro F 2012. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 55: 384-394.
4. Cavalcante LN, Abe-Sandes K, Angelo ALD, Machado TMB, Lemaire DC, Mendes CMC, Pinho JR, Malta F, Lyra LGC, Lyra AC 2012. IL28B polymorphisms are marked of the therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population. Liver Int 32: 476-486.
5. de Araujo ES, Dahari H, Cotler SJ, Layden TJ, Neumann AU, Melo CE, Barone AA 2011. Pharmacodynamics of PEG-IFN-[alpha]-2α and HCV response as a function of IL28B polymorphism in HIV/HCV coinfected patients. J Acquir Immune Defic Syndr 56: 95-99.
6. El-Serag HB 2002. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36 (Suppl.): S74-S83.
7. El-Serag HB, Mason AC 1999. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750.
8. Ferenci P 2004. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 24 (Suppl 2): 25-31.
9. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales Jr FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxì A, Chaneac M, Reddy KR 2005. Predicting sustained virological responses in chronic hepatitis C patients treated with peg-interferon alfa-2a (40 KD)/ribavirin. J Hepatol 43: 425-433.
10. Ferreira PRA, Santos C, Côrtes R, Reis A, Tenoren SB, Silva MH, Vilhena C, Diaz RS 2012. Association between IL28B gene polymorphisms and sustained virological response in patients coinfected with HCV and HIV in Brazil. J Antimicrob Chemother 67: 509-510.
11. Fischer J, Böhm S, Scholz M, Müller T, Witt H, George J, Sarrazin C, Susser S, Schott E, Suppiah V, Booth D, Stwartg J, van Bömmel F, Brodzinski A, Fülop B, Migaud P, Berg T 2012. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type I infection. Hepatology 55: 1700-1710.
12. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales Jr FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J 2002. Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
13. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, Uchiyama H, Soejima Y, Shirabe K, Matsuura Y, Maehara Y 2010. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 139: 1577-1585.
14. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
15. Ghany MG, Strader DB, Thomas DL, Seeff LB 2009. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
16. IBGE-Instituto Brasileiro de Geografia e Estatística 2000. Brasil-500 anos de povoamento. Available from: ibge. gov. br/brasil500/index2. html.
17. Lindh M, Lagging M, Norkrans G, Hellstrand K 2010. A model explaining the correlations between IL28B-related genotypes, hepatitis C virus genotypes and viral RNA levels. Gastroenterology 139: 1794-1796.
18. Lunge VR, da Rocha DB, Béria JU, Tietzmann DC, Stein AT, Simon D 2012. IL28B polymorphism associated with spontaneous clearance of hepatitis C infection in a southern Brazilian HIV type 1 population. AIDS Res Hum Retroviruses 28: 215-219.
19. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
20. Marabita F, Aghemo A, de Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, de Francesco R, Colombo M 2011. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 54: 1127-1134.
21. McHutchison JG, Lawitz EJ, Shiffman ML, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LB, Brass CA, Albrecht JK, Sulkowski MS, IDEAS Study Team 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361: 580-593.
22. McHutchison JG, Shad JA, Gordon SC, Morgan TR, Ling MH, Garaud JJ, Albrecht JK, Dienstag JL 2001. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepat 8: 414-420.
23. Moraes Coelho HS, Villela-Nogueira CA 2010. Predictors of response to chronic hepatitis C treatment. Ann Hepatol 9 (Suppl.): S54-S60.
24. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J 2000. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32: 1131-1137.
25. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study 2010. Gastroenterology 138: 1338-1345.
26. Shebl FM, Maeder D, Shao Y, Prokunina-Olsson L, Schadt EE, O'Brien TR 2010. In the absence of HCV infection, interferon stimulated gene expression in liver is not associated with IL28B genotype. Gastroenterology 139: 1422-1424.
27. Silva R, Moura-Neto RS 2004. Genetic diversity and admixture data on 11 STRs (F13B, TPOX, CSF1PO, F13A01, D7S820, LPL, TH01, vWA, D13S317, FESFPS and D16S539) in a sample of Rio de Janeiro European-descendants population, Brazil. Forensic Sci Int 142: 51-53.
28. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
29. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
30. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG 2010. IL28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of SVR in HCV-1 Patients. Gastroenterology 139: 120-129.
31. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, Kullig U, Göbel U, Capka E, Wiegand J, Schiefke I, Güthoff W, Grüngreiff K, König I, Spengler U, McCarthy J, Shianna KV, Goldstein DB, McHutchison JG, Timm J, Nattermann J, German Anti-D Study Group 2010. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 139: 1586-1592.
32. Villela-Nogueira CA, Perez RM, de Segadas Soares JA, Coelho HS 2005. Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. J Clin Gastroenterol 39: 728-730.